Is Innovation Worth the Price? Cost-Effectiveness Analysis in Interventional Oncology.

Area of Science:

• Health Economics
• Health Technology Assessment (HTA)

Background:

• Cost-Effectiveness Analysis (CEA) is vital for healthcare decision-making and resource allocation.
• Rigorous CEA involves selecting comparators, assessing costs, evaluating outcomes, and using robust modeling.
• Interventional oncology faces challenges with innovative, costly procedures requiring demonstration of long-term benefits.

Purpose of the Study:

• To illustrate how CEA supports evidence-based healthcare policies.
• To demonstrate the application of CEA in interventional oncology.

Main Methods:

• Utilizing a case study by Rognoni et al.
• Comparing transarterial radioembolization (TARE) and sorafenib for liver tumors.
• Applying principles of comprehensive cost assessment and outcome evaluation.

Main Results:

• CEA provides economic evidence to balance clinical effectiveness with resource efficiency.
• Findings from CEA inform value-for-money assessments of medical interventions.
• The case study highlights CEA's role in guiding healthcare policies for liver tumor treatments.

Conclusions:

• CEA is essential for informed healthcare decision-making in HTA.
• Economic evidence from CEA is crucial for adopting innovative oncology treatments.
• CEA, within the broader HTA framework, supports efficient and ethical resource allocation.